Shabnam Tarvirdipour
General Information
Department of Chemistry
University of Basel
Mattenstrasse 24a, BPR-1096
4058 Basel, Switzerland
phone: +41 61 207 10 34
email: shabnam.tarvirdipour@clutterunibas.ch
Projects
Peptide vectors for gene delivery
CV
Studied Chemical Engineering at Sahand University of Technology, Iran. Received Master degree in Chemical Engineering-Biomedical Division from Tarbiat Modares University, Iran; under the mentorship of Prof. Ebrahim Vasheghani-Farahani.
In 2017 moved to Switzerland to pursue a PhD program in Nanoscience under the collaborative supervisions of Prof. Cornelia Palivan and Prof. Yaakov (Kobi) Benenson. The PhD project focuses on interdisciplinary research area in the field of biotechnology and nanomedicine for developing a novel therapeutic delivery system.
Publications
Peptide nanocarriers co-delivering an antisense oligonucleotide and photosensitizer elicit synergistic cytotoxicity [link]
S. Tarvirdipour, M. Skowicki, V. Maffeis, S. N. Abdollahi, C.-A. Schoenenberger, C. G. Palivan
J. Colloid Interface Sci. 2024, DOI: 10.1016/j.jcis.2024.03.021
FAP Targeting of Photosensitizer-Loaded Polymersomes for Increased Light-Activated Cell Killing [link]
M. Skowicki, D. Hürlimann, S. Tarvirdipour, M. Kyropoulou, C.-A. Schoenenberger, S. Gerber-Lemaire, C. G. Palivan
Biomacromolecules2024, DOI: 10.1021/acs.biomac.3c00943
A self-assembling amphiphilic peptide nanoparticle for the efficient entrapment of DNA cargoes up to 100 nucleotides in length [link]
S. Tarvirdipour, C.-A. Schoenenberger, Y. Benenson, C. G. Palivan
Soft Matter, 2020, 16, 1678-1691. DOI: 10.1039/C9SM01990A
Liposome-targeted delivery for highly potent drugs [link]
H Bardania, S Tarvirdipour, F Dorkoosh
Artificial cells, nanomedicine, and biotechnology, 2017,45 (8), 1478-1489.DOI: 10.1080/21691401.2017.1290647
Functionalized magnetic dextran-spermine nanocarriers for targeted delivery of doxorubicin to breast cancer cells [link]
S Tarvirdipour, E Vasheghani-Farahani, M Soleimani, H Bardania
International journal of pharmaceutics, 2016, 501 (1-2), 331-341. DOI: 10.1016/j.ijpharm.2016.02.012